August 16, 2019 - BioPharma Dive
One class of proteins was at the heart of nearly $100 billion worth oncology M&A over the past decade, according to a new report. They're called kinases, and their job is to tack phosphate groups onto various molecules. Like a switch, the reaction can make the receiving molecule more or less active. Kinases therefore play an important role in cell signaling, yet research has shown they can also facilitate cancer growth.
August 16, 2019 - BioPharma Dive
Celgene on Friday won U.S. approval for Inrebic, a treatment for myelofibrosis that is one of five drugs Bristol-Myers Squibb regarded as particularly valuable in its $74 billion deal to buy Celgene. Celgene paid just over $1 billion upfront in January 2018 to acquire Inrebic's latest developer, Impact Biomedicines. As part of that deal, Impact shareholders are entitled to up to $1.4 billion in milestone payments for regulatory approvals in myelofibrosis and other indications.
August 15, 2019 - Fierce Pharma
Sanofi and generic drugmakers have been battling back and forth over patents protecting the company’s top oncology product, Jevtana. In the latest round, Sanofi proved victorious. The decision marks a win for Sanofi as it seeks to get the most out of Jevtana, which was the company’s top oncology product by sales last year and pulled in €422 million. In the first half of 2019, the drug generated €237 million. It’s approved to treat certain prostate cancer patients and won its initial FDA approval in 2010.
August 14, 2019 - Outsourcing-Pharma
The multi-stakeholder group is developing a blockchain-powered platform to increase transparency and collaboration in the clinical trial supply chain – and has successfully completed a proof-of-concept project, now looking to next steps.
August 13, 2019 - Outsourcing-Pharma
Saama Technologies today announced that it has signed a definitive agreement to acquire Comprehend Systems, creating an ‘enhanced suite of complementary capabilities’ to ‘facilitate more rapid drug development,’ says company executives.